[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369904-105":59,"doc-detail-369904-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tp53-pr181h-is-enriched-in-the-swedish-cohort-swep53-and-associated-with-a-distinct-breast-and-prostate-phenotype-research-paper-summary","TP53 p.R181H is enriched in the Swedish cohort (SWEP53) and associated with a distinct breast and prostate phenotype - Research paper summary","","TP53 p.R181H is enriched in the Swedish germline TP53 cohort (SWEP53) and is linked to a distinct phenotype affecting cancer timing, sex-specific tumor types, and overall outcomes. In 22% of SWEP53 families (19/86), p.R181H contrasts sharply with 0.6% in the NCI TP53 database (8/1360). Carriers show lower cancer incidence and better survival (p \u003C 0.0001), with mainly breast cancer in females and prostate cancer in males; no childhood cancers were observed. Tumor sequencing indicates loss of heterozygosity, and haplotype analysis suggests a Swedish founder origin (~550 years). Findings support tailored adult-focused surveillance and require validation in independent cohorts.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tp53-pr181h-is-enriched-in-the-swedish-cohort-swep53-and-associated-with-a-distinct-breast-and-prostate-phenotype-research-paper-summary/369904/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tp53-pr181h-is-enriched-in-the-swedish-cohort-swep53-and-associated-with-a-distinct-breast-and-prostate-phenotype-research-paper-summary/369904.png","ImageObject",300,407,{"name":92,"@type":93},"Blitz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How enriched is TP53 p.R181H in the Swedish SWEP53 cohort compared with the NCI database?","Question",{"text":112,"@type":113},"In SWEP53, p.R181H was identified in 22% of families (19/86). In the NCI TP53 database it was 0.6% (8/1360).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What cancer patterns were observed in p.R181H carriers by sex and age of onset?",{"text":117,"@type":113},"Female carriers primarily developed breast cancer with the earliest onset at 29 years, while male carriers mainly developed prostate cancer with the earliest onset at 45 years. No cancers were observed in children.",{"name":119,"@type":110,"acceptedAnswer":120},"What biological evidence and origin inference support the distinct nature of p.R181H?",{"text":121,"@type":113},"Tumor sequencing confirmed loss of heterozygosity. Haplotype analysis suggests p.R181H is a potential Swedish founder variant estimated to be about 550 years old.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369904,1790472227,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nTP53 p.R181H is enriched in the Swedish cohort (SWEP53) and associated with a distinct breast and prostate phenotype  \nAlexander Sun Zhang1􀀍, Meis Omran1,2, Cecilia Arthur3,4, Helena Malmgren3,4, Rita Barbosa-Matos5,6, Susana Seixas5,6, Carla Oliveira5,6, Emma Tham3,4 & Svetlana Bajalica-Lagercrantz1,2,4  \nLi-Fraumeni Syndrome (LFS) is a severe cancer predisposition syndrome caused by germline TP53 variants and characterized by a wide range of cancers. The TP53 variant p.R181H is enriched in the Swedish germline TP53 cohort and has distinct phenotypical characteristics. Using our nationwide Swedish germline TP53 database (SWEP53, 189 individuals, 86 families), p.R181H was identified in 22% of families (19/86), compared to just 0.6% in the National Cancer Institute (NCI) TP53 database (8/1360) . Notably, p.R181H carriers had lower cancer incidence and better survival than carriers of other TP53 variants (both p \u003C 0.0001). Female carriers primarily developed breast cancer (earliest onset 29 years), males mainly prostate cancer (earliest onset 45 years), and no cancers were observed in children. The results were confirmed using the NCI TP53 database. Tumor sequencing confirmed loss of heterozygosity. Additionally, haplotype analysis suggests that p.R181H is a potential Swedish founder variant, estimated to be ~ 550 years old. These findings indicate that, for p.R181H carriers, tailored surveillance could focus on adults by omitting children from testing and surveillance, and by targeting prevention and detection to breast cancer in females and prostate cancer in males. Validation in independent cohorts is warranted.  \nKeywords Germline TP53, Li-Fraumeni syndrome, Founder, Surveillance  \nLi-Fraumeni Syndrome (LFS), also known as heritable TP53-related cancer syndrome (hTP53rc), is a hereditary cancer predisposition syndrome caused by germline variants in the tumor suppressor gene TP531,2. The syndrome is inherited in an autosomal dominant manner and the lifetime cancer risk is approximately 70% for males and close to 100% for females3,4. Moreover, approximately 50% of affected individuals who develop an initial malignancy will develop a subsequent primary cancer5. Adrenocortical carcinomas (ACC), breast cancers, central nervous system (CNS) tumors, osteosarcomas and soft-tissue sarcomas represent the most frequently observed malignancies and are therefore considered the core cancers of LFS. However, the cancer spectrum is broad and includes a variety of other malignancies, such as leukemia, lung cancer, and skin cancer6,7. LFS patients also display a heterogenous temporal spectrum with certain variants associated with earlier onset of first cancer8. Due to the extreme lifetime cancer risk, current international guidelines recommend intensive tumor screening programs including whole-body magnetic resonance imaging (WB-MRI), abdominal ultrasoundsand clinical check-ups. Unfortunately, these screening programs are often one-size-fits-all and fail to take into consideration the various cancer spectra and temporal distribution exhibited by different TP53 variants1,9.  \nThere is a wide spectrum of TP53 variants that are known to cause LFS, and cohorts usually show a large variant and phenotype heterogeneity. To date, more than 1,500 unique TP53 germline variants have been reported in the National Cancer Institute (NCI) TP53 database10. In certain populations specific germline variants can be enriched and observed in a higher frequency than expected. These variants are known as  \n1Department of Oncology-Pathology, Karolinska Institutet, J6:20 Bioclinicum, Akademiska Stråket 1, 171 77 Stockholm, Sweden. 2Cancer Theme, Karolinska University Hospital, Stockholm, Sweden. 3Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 4Department of Clinical Genetics and Genomics, Karolinska University Hospital, Stockholm, Sweden. 5Institut","cbCaimYlWShItY5u","https://ap.wps.com/l/cbCaimYlWShItY5u","pdf",1359898,11,"English","# TP53 p.R181H enrichment in the Swedish cohort (SWEP53)\n## Clinical phenotype and sex-specific cancer spectrum\n## Methods: SWEP53 database and variant/clinical data","[{\"question\":\"How enriched is TP53 p.R181H in the Swedish SWEP53 cohort compared with the NCI database?\",\"answer\":\"In SWEP53, p.R181H was identified in 22% of families (19/86). In the NCI TP53 database it was 0.6% (8/1360).\"},{\"question\":\"What cancer patterns were observed in p.R181H carriers by sex and age of onset?\",\"answer\":\"Female carriers primarily developed breast cancer with the earliest onset at 29 years, while male carriers mainly developed prostate cancer with the earliest onset at 45 years. No cancers were observed in children.\"},{\"question\":\"What biological evidence and origin inference support the distinct nature of p.R181H?\",\"answer\":\"Tumor sequencing confirmed loss of heterozygosity. Haplotype analysis suggests p.R181H is a potential Swedish founder variant estimated to be about 550 years old.\"}]","TP53 p.R181H is enriched in the Swedish cohort (SWEP53) and associated with a distinct breast and prostate phenotype - Research paper summary | PDF",1790185169,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1814c699d0f43f4b27993a5edee60757.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbf5d44cb244f452fa5e7f611c1f98a8.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce31ec1635976d76f3822256436caaa4.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aea02e68946ab5eee62a4d25501a464c.webp",980,1287]